key: cord-0912382-c1d865ef
authors: Di Landro, Anna; Naldi, Luigi; Glaser, Ella; Paus, Ralf; Tosti, Antonella
title: Pathobiology questions raised by telogen effluvium and trichodynia in COVID‐19 patients
date: 2021-05-04
journal: Exp Dermatol
DOI: 10.1111/exd.14352
sha: 510f3287b1f59d460df51f0d91539df4725f1389
doc_id: 912382
cord_uid: c1d865ef

We recently observed 39 patients in Italy presenting with telogen effluvium, including 7 patients with severe trichodynia. These include 9 men and 30 women ageing 48 to 73 years (mean age 64.6). In 16 patients, COVID-19 presented with severe interstitial pneumonia, requiring hospitalization and Continuous Positive Airway Pressure (CPAP) therapy. Medications included paracetamol (39) systemic steroids ( 25) anticoagulants (16). Symptoms developed eight weeks to three months after clinical manifestations COVID-19.

Although cell receptors binding COVID-19 appear to be less expressed in the skin compared to other organs, 1 skin lesions and hair loss are common manifestations of the disease (Supporting information S1,S2).

We recently observed 39 patients in Italy presenting with telogen effluvium, including 7 patients with severe trichodynia. These include 9 men and 30 women ageing 48 to 73 years (mean age 64.6).

In 16 patients, COVID-19 presented with severe interstitial pneu- 

Potential interactions of SARS-CoV-2 with human cell receptors in the skin: understanding the enigma for a lower frequency of skin lesions compared to other tissues

Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study

Interferon-gamma is a potent inducer of catagen-like changes in cultured human anagen hair follicles

Olfactory receptor OR2AT4 regulates human hair growth

COVID-19-Related Anosmia: the olfactory pathway hypothesis and early intervention